NexCAR19, a meticulously crafted CAR T cell therapy, adds its prominent value to oncology healthcare in India. It recently received approval from The Central Drugs Standard Control Organization (CDSCO) in India. CAR T cell therapy product presents a unique humanized ‘h1CAR19-8BBζ CAR’ construct with its favorable impact on CD4+ and CD8+ T cell subsets, cytokine secretion, … Continue reading NexCAR19 CAR T Cell therapy: Tailoring the Approach